Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

Inclusion Criteria

• •Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time \> 3 months
• •Histological confirmed evidence of relapsed or refractory NK/T cell lymphoma
• •Before enrollment, representative formalin-fixed paraffin-embedded tumor samples (or 15 tissue sections at least) and related pathological reports are needed
• •Previous treatment with at least one chemotherapy regimen
• •At least one measurable lesion
• •None of other serious diseases, cardiopulmonary function is normal
• •Pregnancy test of women at reproductive age must be negative
• •Patients could be followed up
• •None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments.
• •volunteers who signed informed consent.
• •No anti-PD1 antibody contraindication (All of the following tests are required to be finished within 14 days prior to the first research): 2.5×109/L\<WBC\<15×109/L, hemoglobin ≥ 90 g/L, neutrophil≥ 1.5×109/L, lymphocyte≥0.5×109/L, platelet ≥ 100×109/L, serum albumin≥2.5g/dL, ALT and AST ≤ 2×ULN, serum bilirubin≤ 1.5×ULN, serum creatine ≤ 1.5×ULN, Serum Albumin ≥ 30g/L, serum plasminogen is normal, creatinine clearance rate≥30 mL/min, INR≤1.5×ULN, APTT≤1.5×ULN